Literature DB >> 21331782

P53 mutation is a rare event in Merkel cell carcinoma of the head and neck.

Claudia Lill1, Sven Schneider, Chike B Item, Robert Loewe, Roland Houben, Daniel Halbauer, Gregor Heiduschka, Markus Brunner, Dietmar Thurnher.   

Abstract

The aim of this retrospective analysis was to evaluate the status of p53 and possible mutations in Merkel cell carcinoma (MCC) cell lines and MCC tissue samples. The p53 mutations are common in different cancer origins but rare in MCCs detected so far. MCCs are highly aggressive neuroendocrine tumors with an enhanced potential to metastasize. Until now, less is known about MCC and new approaches to understand this disease are necessary. RNA and DNA were extracted from two MCC cell lines and 27 archival paraffin-embedded patient samples. After reverse transcription, a real-time PCR and a high-resolution melt analysis were carried out. In both MCC cell lines, we could detect a p53 missense mutation at codon 193 (exon 6) with a change in amino acids (His → Leu). This mutation was equal in both cell lines and was investigated in 27 tissue samples in succession to detect possible accounts for the aggressive behavior of MCCs. Unfortunately, no corresponding p53 mutation could be observed in the investigated tissue samples. A new p53 mutation was detected in MCC cell lines. This mutation could not be determined in patients' samples. Therefore, the aggressiveness of MCC seems to be independent of p53 mutations and other mutations might be responsible for developing MCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21331782     DOI: 10.1007/s00405-011-1529-7

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  30 in total

1.  Expression and mutation patterns of p53 in benign and malignant salivary gland tumors.

Authors:  A Nordkvist; E Röijer; G Bang; H Gustafsson; M Behrendt; W Ryd; S Thoresen; K Donath; G Stenman
Journal:  Int J Oncol       Date:  2000-03       Impact factor: 5.650

Review 2.  Updated review of the pathogenesis and management of Merkel cell carcinoma.

Authors:  Anna Zampetti; Claudio Feliciani; Guido Massi; Antonello Tulli
Journal:  J Cutan Med Surg       Date:  2010 Mar-Apr       Impact factor: 2.092

Review 3.  Lessons from immune responses and vaccines against murine polyomavirus infection and polyomavirus-induced tumours potentially useful for studies on human polyomaviruses.

Authors:  Torbjörn Ramqvist; Tina Dalianis
Journal:  Anticancer Res       Date:  2010-02       Impact factor: 2.480

4.  Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer.

Authors:  P Guldberg; T Nedergaard; H J Nielsen; A C Olsen; V Ahrenkiel; J Zeuthen
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

5.  UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas.

Authors:  Susanne Popp; Stefan Waltering; Christel Herbst; Ingrid Moll; Petra Boukamp
Journal:  Int J Cancer       Date:  2002-05-20       Impact factor: 7.396

6.  Merkel cell carcinoma. Prognosis and management.

Authors:  A Yiengpruksawan; D G Coit; H T Thaler; C Urmacher; W K Knapper
Journal:  Arch Surg       Date:  1991-12

7.  p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma.

Authors:  Anita Lassacher; Ellen Heitzer; Helmut Kerl; Peter Wolf
Journal:  J Invest Dermatol       Date:  2008-01-24       Impact factor: 8.551

8.  Upregulation of Igf and Wnt signalling associated genes in pleomorphic adenomas of the salivary glands in PLAG1 transgenic mice.

Authors:  Jeroen Declercq; Frederik Van Dyck; Boudewijn Van Damme; Wim J M Van de Ven
Journal:  Int J Oncol       Date:  2008-05       Impact factor: 5.650

9.  TP53 mutations in salivary gland neoplasms.

Authors:  Luciana Fasanella Matizonkas-Antonio; Ricardo Alves de Mesquita; Suzana C Orsini Machado de Souza; Fabio Daumas Nunes
Journal:  Braz Dent J       Date:  2005

10.  Merkel cell carcinoma subgroups by Merkel cell polyomavirus DNA relative abundance and oncogene expression.

Authors:  Kishor Bhatia; James J Goedert; Rama Modali; Liliana Preiss; Leona W Ayers
Journal:  Int J Cancer       Date:  2010-05-01       Impact factor: 7.396

View more
  9 in total

1.  Analysis of p53 transactivation domain mutants reveals Acad11 as a metabolic target important for p53 pro-survival function.

Authors:  Dadi Jiang; Edward L LaGory; Daniela Kenzelmann Brož; Kathryn T Bieging; Colleen A Brady; Nichole Link; John M Abrams; Amato J Giaccia; Laura D Attardi
Journal:  Cell Rep       Date:  2015-02-19       Impact factor: 9.423

Review 2.  A cornucopia of human polyomaviruses.

Authors:  James A DeCaprio; Robert L Garcea
Journal:  Nat Rev Microbiol       Date:  2013-03-11       Impact factor: 60.633

3.  Expression of β-catenin and cyclin D1 in Merkel cell carcinomas of the head and neck.

Authors:  Claudia Lill; Sven Schneider; Bahil Ghanim; Markus Brunner; Gregor Heiduschka; Robert Loewe; Dietmar Thurnher
Journal:  Wien Klin Wochenschr       Date:  2013-08-09       Impact factor: 1.704

4.  Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus.

Authors:  Scott J Rodig; Jingwei Cheng; Jacek Wardzala; Andrew DoRosario; Jessica J Scanlon; Alvaro C Laga; Alejandro Martinez-Fernandez; Justine A Barletta; Andrew M Bellizzi; Subhashini Sadasivam; Dustin T Holloway; Dylan J Cooper; Thomas S Kupper; Linda C Wang; James A DeCaprio
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

5.  Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities.

Authors:  Jingwei Cheng; Orit Rozenblatt-Rosen; Kelly G Paulson; Paul Nghiem; James A DeCaprio
Journal:  J Virol       Date:  2013-03-20       Impact factor: 5.103

Review 6.  Mutational analysis of merkel cell carcinoma.

Authors:  Derek J Erstad; James C Cusack
Journal:  Cancers (Basel)       Date:  2014-10-17       Impact factor: 6.639

7.  Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.

Authors:  Philip R Cohen; Brett N Tomson; Sheryl K Elkin; Erica Marchlik; Jennifer L Carter; Razelle Kurzrock
Journal:  Oncotarget       Date:  2016-04-26

8.  Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma.

Authors:  Varsha Ananthapadmanabhan; Thomas C Frost; Kara M Soroko; Aine Knott; Brianna J Magliozzi; Prafulla C Gokhale; Vijaya G Tirunagaru; Robert C Doebele; James A DeCaprio
Journal:  JCI Insight       Date:  2022-07-08

9.  Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.

Authors:  Gerald Goh; Trent Walradt; Vladimir Markarov; Astrid Blom; Nadeem Riaz; Ryan Doumani; Krista Stafstrom; Ata Moshiri; Lola Yelistratova; Jonathan Levinsohn; Timothy A Chan; Paul Nghiem; Richard P Lifton; Jaehyuk Choi
Journal:  Oncotarget       Date:  2016-01-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.